The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
PurposeTo systematically evaluate the effect of Sodium-glucose cotransporter 2 (SGLT2) inhibitors on adipose tissue in patients with type 2 diabetes.MethodsWe searched PubMed, Cochrane Library, EMBASE, and Web of science databases for literature pertaining to Randomized controlled trials (RCTs) of S...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1115321/full |
| _version_ | 1811176979236388864 |
|---|---|
| author | Xindong Liu Ying Chen Tao Liu Ling Cai Xiaofeng Yang Chuan Mou |
| author_facet | Xindong Liu Ying Chen Tao Liu Ling Cai Xiaofeng Yang Chuan Mou |
| author_sort | Xindong Liu |
| collection | DOAJ |
| description | PurposeTo systematically evaluate the effect of Sodium-glucose cotransporter 2 (SGLT2) inhibitors on adipose tissue in patients with type 2 diabetes.MethodsWe searched PubMed, Cochrane Library, EMBASE, and Web of science databases for literature pertaining to Randomized controlled trials (RCTs) of SGLT2 inhibitors in treating type 2 diabetes patients. The retrieval time was from the date of establishment of the databases to September 1, 2022. Meta-analysis was performed using RevMan5.4 software.ResultsTotally 551 patients were included in 10 articles. Meta-analysis results showed that compared with the control group, the visceral adipose tissue (WMD = -16.29 cm2, 95% CI: -25.07 ~ -7.50, P<0.00001), subcutaneous adipose tissue (WMD = -19.34 cm2, 95% CI: -36.27 ~ -2.41, P<0.00001), body weight (WMD = -2.36 kg, 95% CI: -2.89 ~ -1.83, P<0.00001) and triglyceride (WMD = -24.41 mg/dl, 95% CI: -45.79 ~ -3.03, P = 0.03) of the trial group significantly reduced.ConclusionSGLT2 inhibitors cause significant reductions in visceral adipose tissue, subcutaneous adipose tissue, body weight and triglycerides in type 2 diabetes patients, which may be attributed to the protective effect of the inhibitors on cardiovascular system. |
| first_indexed | 2024-04-10T20:01:52Z |
| format | Article |
| id | doaj.art-ccea026ef4bf443a982f7d197615e0e0 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-10T20:01:52Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-ccea026ef4bf443a982f7d197615e0e02023-01-27T05:37:35ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-01-011410.3389/fendo.2023.11153211115321The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trialsXindong LiuYing ChenTao LiuLing CaiXiaofeng YangChuan MouPurposeTo systematically evaluate the effect of Sodium-glucose cotransporter 2 (SGLT2) inhibitors on adipose tissue in patients with type 2 diabetes.MethodsWe searched PubMed, Cochrane Library, EMBASE, and Web of science databases for literature pertaining to Randomized controlled trials (RCTs) of SGLT2 inhibitors in treating type 2 diabetes patients. The retrieval time was from the date of establishment of the databases to September 1, 2022. Meta-analysis was performed using RevMan5.4 software.ResultsTotally 551 patients were included in 10 articles. Meta-analysis results showed that compared with the control group, the visceral adipose tissue (WMD = -16.29 cm2, 95% CI: -25.07 ~ -7.50, P<0.00001), subcutaneous adipose tissue (WMD = -19.34 cm2, 95% CI: -36.27 ~ -2.41, P<0.00001), body weight (WMD = -2.36 kg, 95% CI: -2.89 ~ -1.83, P<0.00001) and triglyceride (WMD = -24.41 mg/dl, 95% CI: -45.79 ~ -3.03, P = 0.03) of the trial group significantly reduced.ConclusionSGLT2 inhibitors cause significant reductions in visceral adipose tissue, subcutaneous adipose tissue, body weight and triglycerides in type 2 diabetes patients, which may be attributed to the protective effect of the inhibitors on cardiovascular system.https://www.frontiersin.org/articles/10.3389/fendo.2023.1115321/fullSodium-glucose cotransporter 2 inhibitorsSGLT2type 2 diabetesadipose tissuemeta-analysis |
| spellingShingle | Xindong Liu Ying Chen Tao Liu Ling Cai Xiaofeng Yang Chuan Mou The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials Frontiers in Endocrinology Sodium-glucose cotransporter 2 inhibitors SGLT2 type 2 diabetes adipose tissue meta-analysis |
| title | The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials |
| title_full | The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials |
| title_fullStr | The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials |
| title_short | The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials |
| title_sort | effects of sodium glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes a meta analysis of randomized controlled trials |
| topic | Sodium-glucose cotransporter 2 inhibitors SGLT2 type 2 diabetes adipose tissue meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1115321/full |
| work_keys_str_mv | AT xindongliu theeffectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT yingchen theeffectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT taoliu theeffectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT lingcai theeffectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT xiaofengyang theeffectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT chuanmou theeffectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT xindongliu effectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT yingchen effectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT taoliu effectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT lingcai effectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT xiaofengyang effectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials AT chuanmou effectsofsodiumglucosecotransporter2inhibitorsonadiposetissueinpatientswithtype2diabetesametaanalysisofrandomizedcontrolledtrials |